GRB2 and acute myeloid leukemia: With over 50% of AML patients having tyrosine kinase-related mutations (i.e., FLT3-ITD, c-kit, JAK2) that require enhanced Grb2 activity to drive oncogenic pathways [61], inhibiting Grb2 is an interesting therapeutic target.